Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

One year effectiveness of neuromuscular exercise compared with instruction in analgesic use on knee function in patients with early knee osteoarthritis:the EXERPHARMA randomized trial

Tytuł :
One year effectiveness of neuromuscular exercise compared with instruction in analgesic use on knee function in patients with early knee osteoarthritis:the EXERPHARMA randomized trial
Autorzy :
Holsgaard-Larsen, A
Christensen, R
Clausen, B
Søndergaard, J
Andriacchi, T P
Roos, E M
Pokaż więcej
Temat :
Journal Article
Knee
Knee joint
Exercise
Pain management
Osteoarthritis
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
Prospective Studies
Follow-Up Studies
Humans
Middle Aged
Patient Education as Topic/methods
Analgesics, Non-Narcotic/therapeutic use
Male
Treatment Outcome
Pamphlets
Activities of Daily Living
Osteoarthritis, Knee/therapy
Acetaminophen/therapeutic use
Female
Aged
Exercise Therapy/methods
Drug Therapy, Combination
Źródło :
Holsgaard-Larsen, A, Christensen, R, Clausen, B, Søndergaard, J, Andriacchi, T P & Roos, E M 2018, ' One year effectiveness of neuromuscular exercise compared with instruction in analgesic use on knee function in patients with early knee osteoarthritis : the EXERPHARMA randomized trial ', Osteoarthritis and Cartilage, vol. 26, no. 1, pp. 28-33 . https://doi.org/10.1016/j.joca.2017.10.015
Rok publikacji :
2018
Kolekcja :
University_of_Southern_Denmark_Research_Output
Język :
English
ISSN :
1063-4584
DOI :
10.1016/j.joca.2017.10.015
Numer akcesji :
edsair.od......3062..11e8e2cc291e3e4d981e681f9c8cbef8
OBJECTIVE: To test long-term effectiveness of neuromuscular exercise (NEMEX) with instructions in optimized pharmacological treatment (PHARMA) on activities of daily living (ADL) in patients with early knee osteoarthritis.DESIGN: 12-months follow-up from a randomized controlled trial. Participants with mild-to-moderate medial tibiofemoral knee osteoarthritis were randomly allocated to 8 weeks NEMEX or PHARMA. The primary outcome measure was the ADL-subscale of the Knee Injury and Osteoarthritis Outcome Score (KOOS). Secondary outcome measures included the other four KOOS-subscales, the University of California Activity Score (UCLA) and the European Quality of Life-5 Dimensions.RESULTS: Ninety-three patients (57% women, 58 ± 8 years, body mass index 27 ± 4 kg/m(2)) were randomized to NEMEX (n = 47) or PHARMA group (n = 46) with data from 85% being available at 12-months follow-up. Good compliance was achieved for 49% of the participants in NEMEX (≥12 sessions) and 7% in PHARMA (half the daily dose of acetaminophen/NSAIDs ≥ 28 days). Within-group improvements in NEMEX were considered to be clinically relevant (≥10 points) for all KOOS-subscales, except Sport/Rec whereas, no between-groups difference in the primary outcome KOOS ADL (3.6 [-2.1 to 9.2]; P = 0.216) was observed. For KOOS Symptoms, a statistically significant difference of 7.6 points (2.6-12.7; P = 0.004) was observed in favor of NEMEX with 47% improving ≥10 points.CONCLUSIONS: No difference in improvement in difficulty with ADL was observed. NEMEX improved knee symptoms to a greater extent with half of patients reporting clinically relevant improvements. CLINICALTRIALS.GOV IDENTIFIER: NCT01638962 (July 3, 2012).ETHICAL COMMITTEE: S-20110153.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies